生物活性
CCG-222740 is a selective, orally active Rho/myocardin-related transcription factor (MRTF) pathway inhibitor. CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 markedly decreased SRF reporter gene activity and showed a greater inhibitory effect on MRTF/SRF target genes than the previously described MRTF-A inhibitor CCG-203971. CCG-222740 increases the protein levels of p27 and decreased cyclin D1. CCG-222740 treatment decreased cell viability of CAFs, with an IC50 of~10 μM.
In vivo, CCG-222740 (100 mg/kg; oral gavage for 7 days) significantly reduces α-SMA levels in the pancreas of caerulein-stimulated KC mice.
化学数据
分子量 | 444.86 |
分子式 | C23H19ClF2N2O3 |
CAS号 | 1922098-69-8 |
纯度 | >99% |
溶解性(25°C) | DMSO 90 mg/mL |
储存和运输条件 | 固体粉末: -20°C 冷藏长期储存 常温运输及临时存放 |
实验操作 来自于公开的文献,仅供相同实验参考(如实验材料、目的不同,请参考其他文献)
细胞实验 |
---|
细胞系 | Cancer associated fibroblasts (CAFs) |
方法 | Murine cancer associated fibroblasts (CAFs) are cultured in DMEM supplemented with 10% fetal bovine serum(FBS). CAFs are treated with several concentrations of CCG-222740 (740) for 72 hours, and levels of Cyclin D1 and p27 are evaluated by western blot. |
浓度 | 10 μM |
处理时间 | 72 h |
动物实验 |
---|
动物模型 | Nine-week old KC mice |
配制 | dissolved in 15% (v/v) DMSO and then added to a solution of 10% tween-20 in saline |
剂量 | 100 mg/kg |
给药处理 | Oral gavage; daily; for 7 days |
不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)
| 小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 |
重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km系数 | 3 | 6 | 12 | 8 | 5 | 20 |
动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
储备液配制
以下数据基于产品分子量,对于特殊产品,请参照COA中的储备液配制条件和说明进行操作。
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.2479 mL | 11.2395 mL | 22.479 mL |
5 mM | 0.4496 mL | 2.2479 mL | 4.4958 mL |
10 mM | 0.2248 mL | 1.1239 mL | 2.2479 mL |